Regulatory roles of the ligand for Flk2/Flt3 tyrosine kinase receptor on human hematopoiesis

Stem Cells

Volumn 14, Issue 4, 1996, Pages 388-395

  Namikawa, Reiko ^a   Muench, Marcus O ^a   Roncarolo, Maria Grazia ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Flk2 Flt3 ligand; Growth factor; Hematopoiesis; Kit ligand; Progenitor cells; Tyrosine kinase receptor

Indexed keywords

COLONY STIMULATING FACTOR 1; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3; INTERLEUKIN 7; PROTEIN TYROSINE KINASE; STEM CELL FACTOR;

CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; ERYTHROPOIESIS; HEMATOPOIESIS; HUMAN; LYMPHOPOIESIS; MYELOPOIESIS; NONHUMAN; PROMYELOCYTE; REVIEW;

EID: 0029798251     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.140388     Document Type: Review

References (69)

1. Stanley ER, Guilbert LJ, Tushinski RJ et al. CSF-1-a mononuclear phagocyte lineage-specific hemopoietic growth factor. J Cell Biochem 1983;21:151-159.
2. Sherr CJ, Rettenmier CW, Sacca R et al. The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF-1. Cell 1985;41:665-676.
3. Anderson DM, Lyman SD, Baird A et al. Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms. Cell 1990;63:235-243.
4. Huang E, Nocka K, Beier DR et al. The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit receptor, the gene product of the W locus. Cell 1990;63:225-233.
5. Zsebo KM, Wypych J, McNiece IK et al. Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver-conditioned medium. Cell 1990;63:195-201.
6. Hoffman R, Tong J, Brandt J et al. The in vitro and in vivo effects of stem cell factor on human hematopoiesis. STEM CELLS 1993;11(suppl 2):76-82.
7. Galli SJ, Zsebo KM, Geissler EN. The kit ligand, stem cell factor. Adv Immunol 1994;55:1-96.
8. Rosnet O, Marchetto S, deLapeyriere O et al. Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family. Oncogene 1991;6:1641-1650.
9. Matthews W, Jordan CT, Wiegand GW et al. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell 1991;65:1143-1152.
10. Rosnet O, Schiff C, Pebusque MJ et al. Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood 1993;82:1110-1119.
11. + human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci USA 1994;91:459-463.
12. Birg F, Courcoul M, Rosnet O et al. Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages. Blood 1992;80:2584-2593.
13. Lyman SD, James L, Vanden Bos T et al. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell 1993;75:1157-1167.
14. Hannum C, Culpepper J, Camphell D et al. Ligand tor FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature 1994;368:643-648.
15. Lyman SD, James L, Johnson L et al. Cloning of the human homologue of the murine flt3 ligand: a growth factor for early hematopoietic progenitor cells. Blood 1994;83:2795-2801.
16. Lyman SD, Brasel K, Rousseau AM et al. The flt3 ligand: a hematopoietic stem cell factor whose activities are distinct from the Steel factor. STEM CELLS 1994;12(suppl 1):99-110.
17. Muench MO, Roncarolo MG, Menon S et al. FLK-2/FLT-3 ligand regulates the growth of early myeloid progenitors isolated from human fetal liver. Blood 1995;85:963-972.
18. + human fetal liver progenitors with a high proliferative potential. Blood 1994;83:3170-3181.
19. - murine hematopoietic progenitors. Exp Hematol 1991;19:994-996.
20. Lowry PA, Deacon D, Whitefield P et al. Stem cell factor induction of in vitro murine hematopoietic colony formation by "subliminal" cytokine combinations: the role of "anchor factors". Blood 1992;80:663-669.
21. Heimfeld S, Hudak S, Weissman I et al. The in vitro response of phenotypically defined mouse stem cells and myeloerythroid progenitors to single or multiple growth factors. Proc Natl Acad Sci USA 1991;88:9902-9906.
22. Ogawa M. Differentiation and proliferation of hematopoietic stem cells. Blood 1993;81:2844-2853.
23. 0 and entry into the cell cycle of primitive human hernopoietic progenitors. Proc Natl Acad Sci USA 1992;89:4013-4017.
24. Katayama N, Clark SC, Ogawa M. Growth factor requirement for survival in cell-cycle dormancy of primitive murine lymphohematopoietic progenitors. Blood 1993;81:610-616.
25. Brandt JE, Bhalla K, Hoffman R. Effects of interleukin-3 and c-kit ligand on the survival of various classes of human hematopoietic progenitor cells. Blood 1994;83:1507-1514.
26. Hodgson G, Bradley T. Properties of haematopoietic stem cells surviving 5-fluorouracil treatment: evidence for a pre-CFU-S cell? Nature 1979;281:381-382.
27. 0 periods and constant doubling rates of early pluripotent hemopoietic progenitors. J Cell Physiol 1983;117:308-318.
28. Lemischka IR, Raulet DH, Mulligan RC. Developmental potential and dynamic behavior of hematopoietic stem cells. Cell 1986;45:917-927.
29. Snodgrass R, Keller G. Clonal fluctuation within the haematopoietic system of mice reconstituted with retrovirus-infected stem cells. EMBO 1987;6:3955-3960.
30. v mice. Proc Natl Acad Sci USA 1989;86:4564-4568.
31. Gabbianelli M, Pelosi E, Montesoro E et al. Multi-level effects of flt3 ligand on human hematopoiesis: expansion of putative stem cells and proliferation of granulomonocytic progenitors/monocytic precursors. Blood 1995;86:1661-1670.
32. Broxmeyer HE, Lu L, Cooper S et al. Flt3 ligand stimulates/costimulates the growth of myeloid stem/progenitor cells. Exp Hematol 1995;23:1121-1129.
33. Namikawa R, Muench MO, de Vries JE et al. The FLK2/FLT3 ligand synergizes with IL-7 in promoting stromal-cell-independent expansion and differentiation of human fetal pro-B cells in vitro. Blood 1996;87:1881-1890.
34. Niemeyer CM, Sieff CA, Mathey PB et al. Expression of human interleukin-3 (multi-CSF) is restricted to human lymphocytes and T-cell tumor lines. Blood 1989;73:945-951.
35. Ikuta K, Weissman IL. Evidence that hematopoietic stem cells express mouse c-kit but do not depend on Steel factor for their generation. Proc Natl Acad Sci USA 1992;89:1502-1506.
36. Kodama H, Nose M, Yamaguchi Y et al. In vitro proliferation of primitive hemopoietic stem cells supported by stromal cells: evidence for the presence of a mechanism(s) other than that involving c-kit receptor and its ligand. J Exp Med 1992;176:351-361.
37. Wineman JP, Nishikawa S, Muller-Sieburg CE. Maintenance of high levels of pluripotent hematopoietic stem cells in vitro: effect of stromal cells and c-kit. Blood 1993;81:365-372.
38. Hudak S, Hunte B, Culpepper J et al. FLT3/FLK2 ligand promotes the growth of murine stem cells and the expansion of colony-forming cells and spleen colony-forming units. Blood 1995;85:2747-2755.
39. Hirayama F, Lyman SD, Clark SC et al. The flt3 ligand supports proliferation of lymphohematopoietic progenitors and early B-lymphoid progenitors. Blood 1995;85:1762-1768.
40. Jacobsen SE, Okkenhaug C, Myklebust J et al. The FLT3 ligand potently and directly stimulates the growth and expansion of primitive murine bone marrow progenitor cells in vitro: synergistic interactions with interleukin (IL) 11, IL-12, and other hematopoietic growth factors. J Exp Med 1995;181:1357-1363.
41. Hunt B, Hudak ES, Campbell D et al. flk2/flt3 ligand is a potent cofactor for the growth of primitive B cell progenitors. J Immunol 1996;156:489-496.
42. v mice and their increase by bone marrow transplantation. Blood 1978;52:447-452.
43. d anemic mice. Blood 1978;53:492-497.
44. Russell ES. Hereditary anemias of the mouse: a review for geneticists. Adv Genet 1979;20:357-459.
45. Mackarehtschian K, Hardin JD, Moore KA et al. Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity 1995;3:147-161.
46. Hirayama F, Clark SC, Ogawa M. Negative regulation of early B lymphopoiesis by interleukin 3 and interleukin 1 alpha. Proc Natl Acad Sci USA 1994;91:469-473.
47. McCune JM, Namikawa R, Kaneshima H et al. The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science 1988;241:1632-1639.
48. Namikawa R, Weilbaecher KN, Kaneshima H et al. Long-term human hematopoiesis in the SCID-hu mouse. J Exp Med 1990;172:1055-1063.
49. Kyoizumi S, Baum CM, Kaneshima H et al. Implantation and maintenance of functional human bone marrow in SCID-hu mice. Blood 1992;79:1704-1711.
50. Di Giusto D, Chen S, Combs J et al. Human fetal bone marrow early progenitors for T, B, and myeloid cells are found exclusively in the population expressing high levels of CD34. Blood 1994;84:421-432.
51. Chen BP, Galy A, Kyoizumi S et al. Engraftment of human hematopoietic precursor cells with secondary transfer potential in SCID-hu mice. Blood 1994;84:2497-2505.
52. Yoshimura A, Longmore G, Lodish HF. Point mutation in the exoplasmic domain of the erythropoietin receptor resulting in hormone-independent activation and tumorigenicity. Nature 1990;348:647-649.
53. Chretien S, Moreau-Gachelin F, Apiou F et al. Putative oncogenic role of the erythropoietin receptor in murine and human erythroleukemia cells. Blood 1994;83:1813-1821.
54. Roussel MF, Downing JR, Rettenmier CW et al. A point mutation in the extracellular domain of the human CSF-1 receptor (c-fms proto-oncogene product) activates its transforming potential. Cell 1988;55:979-988.
55. Tobal K, Pagliuca A, Bhatt B et al. Mutation of the human FMS gene (M-CSF receptor) in myelodysplastic syndromes and acute myeloid leukemia. Leukemia 1990;4:486-489.
56. Natazuka T, Matsui T, Ito M et al. Rare point mutation at codon 301 and 969 of FMS/M-CSF receptor in acute myelomonocytic and monocytic leukemia. Leuk Res 1992;16:541-543.
57. Dong F, van Paassen M, van Buitenen C et al. A point mutation in the granulocyte colony-stimulating factor receptor (G-CSF-R) gene in a case of acute myeloid leukemia results in the overexpression of a novel G-CSF-R isoform. Blood 1995;85:902-911.
58. Socinski MA, Cannistra SA, Elias A et al. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1988;1:1194-1198.
59. Peters WP, Rosner G, Ross M et al. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993;81:1709-1719.
60. Sheridan WP, Begley CG, Juttner CA et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992;339:640-644.
61. + colony-forming cell types in blood and marrow of baboons. Blood 1992;80:920-927.
62. Brugger W, Bross K, Frisch J et al. Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifostamide, and cisplatin. Blood 1992;79:1193-1200.
63. Estey EH, Dixon D, Kantarjian HM et al. Treatment of poor-prognosis, newly diagnosed acute myeloid leukemia with ara-C and recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1990;75:1766-1779.
64. Kitano K, Kobayashi H, Maeyama H et al. Treatment of acute monoblastic leukaemia by combination of recombinant human macrophage colony-stimulating factor and low dose of ara-C. Br J Haematol 1993;85:176-178.
65. Goto H, Shimazaki C, Hirata T et al. Recombinant human granulocyte colony-stimulating factor in combination with continuous infusion of cytosine arabinoside for the treatment of refractory acute myelogenous leukemia. Acta Haematol 1993;89:144-148.
66. Cannistra SA, Di Carlo J, Groshek P et al. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia. Leukemia 1991;5:230-238.
67. Costa JJ, Demetri GD, Hayes DF et al. Increased skin mast cells and urine methyl histamine in patients receiving recombinant methionyl human stem cell factor. Proc Am Assoc Cancer Res 1993;34:211a.
68. Demetri G, Costa J, Hayes D et al. A phase I trial of recombinant methionyl human stem cell factor (SCF) in patients with advanced breast carcinoma pre- and post-chemotherapy (chemo) with cyclophosphamide (C) and doxorubicin (A). Proc Am Soc Clin Oncol 1993;12:367a.
69. Kyoizumi S, Murray LJ, Namikawa R. Preclinical analysis of cytokine therapy in the SCID-hu mouse. Blood 1993;81:1479-1488.